Connie Wong1, Shaojie Zhang1, Ervin Adam1, Lawrence Paszat2, Janet S Butel3. 1. Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, MS: BCM385, Houston, TX 77030, USA. 2. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. 3. Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, MS: BCM385, Houston, TX 77030, USA. Electronic address: jbutel@bcm.edu.
Abstract
OBJECTIVES: This study sought to determine SV40 seroprevalence in residents of two Latin American countries, Colombia and Nicaragua, which were sites of prelicensure oral poliovaccine (OPV) trials. METHODS: Archival sera were tested for SV40 neutralizing antibody using a virus-specific plaque-reduction assay. Samples included 517 sera from Colombia and 149 sera from Nicaragua. RESULTS: Overall SV40 seroprevalence was 22.8% for Colombian subjects and 12.8% for Nicaraguans. Subgroups of Colombian subjects ranged in frequency of SV40 seropositivity from 10.0% to 38.6%. Birth cohorts both older and younger than the age cohort that contained potential OPV vaccinees from both countries had SV40 antibodies. Gender and ethnicity had no significant effects on SV40 seropositivity. CONCLUSIONS: Inhabitants of both Colombia and Nicaragua had detectable SV40 neutralizing antibody, including those of ages presumably not recipients of potentially SV40-contaminated OPV. This observation provides support for the concept that transmission of SV40 human infections can occur. Frequency of SV40 antibody positivity was elevated over that reported for the US where there was limited use of contaminated OPV. This investigation indicates also that study results of SV40 infections in humans will reflect whether subject populations had probable exposures to contaminated poliovaccines and to environmental conditions favoring cycles of viral transmission.
OBJECTIVES: This study sought to determine SV40 seroprevalence in residents of two Latin American countries, Colombia and Nicaragua, which were sites of prelicensure oral poliovaccine (OPV) trials. METHODS: Archival sera were tested for SV40 neutralizing antibody using a virus-specific plaque-reduction assay. Samples included 517 sera from Colombia and 149 sera from Nicaragua. RESULTS: Overall SV40 seroprevalence was 22.8% for Colombian subjects and 12.8% for Nicaraguans. Subgroups of Colombian subjects ranged in frequency of SV40 seropositivity from 10.0% to 38.6%. Birth cohorts both older and younger than the age cohort that contained potential OPV vaccinees from both countries had SV40 antibodies. Gender and ethnicity had no significant effects on SV40 seropositivity. CONCLUSIONS: Inhabitants of both Colombia and Nicaragua had detectable SV40 neutralizing antibody, including those of ages presumably not recipients of potentially SV40-contaminated OPV. This observation provides support for the concept that transmission of SV40 humaninfections can occur. Frequency of SV40 antibody positivity was elevated over that reported for the US where there was limited use of contaminated OPV. This investigation indicates also that study results of SV40 infections in humans will reflect whether subject populations had probable exposures to contaminated poliovaccines and to environmental conditions favoring cycles of viral transmission.
Authors: F SERPA-FLOREZ; D MALDONADO-ROMERO; A ARGUELLO-PINZON; A BAHAMON-SOTO; H PINEROS-BERNAL Journal: Pediatrics Date: 1964-06 Impact factor: 7.124
Authors: Wendy A Knowles; Pam Pipkin; Nick Andrews; Andrew Vyse; Philip Minor; David W G Brown; Elizabeth Miller Journal: J Med Virol Date: 2003-09 Impact factor: 2.327
Authors: Dana E M Rollison; Kathy J Helzlsouer; Anthony J Alberg; Sandra Hoffman; Jean Hou; Richard Daniel; Keerti V Shah; Eugene O Major Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-05 Impact factor: 4.254
Authors: J S Butel; C Wong; R A Vilchez; G Szücs; I Dömök; B Kríz; D Slonim; E Adam Journal: Cent Eur J Public Health Date: 2003-03 Impact factor: 1.163
Authors: Rui-Mei Li; Mary H Branton; Somsak Tanawattanacharoen; Ronald A Falk; J Charles Jennette; Jeffrey B Kopp Journal: J Am Soc Nephrol Date: 2002-09 Impact factor: 10.121